The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology

Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns abou...

Descripción completa

Detalles Bibliográficos
Autores principales: Tayeb, Haythum O., Khallaf, Roaa A., Muayqil, Taim A., Alkeridy, Walid A., Alibrahim, Fawwaz S., Alfaify, Omar A., Qadi, Najeeb, Tarazi, Frank I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Riyadh : Armed Forces Hospital 2023
Materias:
Clinical Practice Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155484/
https://www.ncbi.nlm.nih.gov/pubmed/37045461
http://dx.doi.org/10.17712/nsj.2023.2.20220133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155484/
https://www.ncbi.nlm.nih.gov/pubmed/37045461
http://dx.doi.org/10.17712/nsj.2023.2.20220133

Ejemplares similares